Evidence map›Paper›PMID 41960563›Full record

ArticleAsia Pacific allergy2026

Clinical outcomes of 2-year

Change Fan, Huijiao Cai, Xin Tong, Tingting Ma, Yanfei Li, Liya Ai, Xueyan Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asia Pacific allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Change FanDepartment of Allergy, First Hospital of Hohhot, Hohhot, Inner Mongolia, China.
Huijiao CaiDepartment of Allergy, First Hospital of Hohhot, Hohhot, Inner Mongolia, China.
Xin TongDepartment of Allergy, First Hospital of Hohhot, Hohhot, Inner Mongolia, China.
Tingting MaDepartment of Allergy, Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing, China.
Yanfei LiDepartment of Allergy, First Hospital of Hohhot, Hohhot, Inner Mongolia, China.
Liya AiDepartment of Allergy, First Hospital of Hohhot, Hohhot, Inner Mongolia, China.
Xueyan WangDepartment of Allergy, Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pollen immunotherapy has increasingly gained attention in China. However, the majority of existing research is limited to evaluating therapeutic effects within a 1-year treatment period, with insufficient evidence regarding the longer-term course of treatment. Objectives: Our study was designed to evaluate the clinical effectiveness and safety of 2-year Methods: This study was conducted as a nonblind randomized controlled trial. Fifty eligible patients (7-57 years old) sensitized to Results: Finally, 43 patients (SLIT: 21, control: 22) completed this study. When compared with the control group, the patients in SLIT group exhibited remarkable improvements in TRSS, TMS, CSMRS, and VAS scores during the 2023 pollen season ( Conclusions: Two years of

Indexed as

Allergic rhinoconjunctivitisArtemisia annuaefficacysafetysublingual immunotherapy

Identifiers

PMID41960563
PMCPMC13060872

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.